MMI-0100, a cell-permeant peptide inhibitor of mitogen-activated protein kinase activated protein kinase II (MK2), effectively reduces intimal hyperplasia ex vivo and in vivo. It specifically suppresses IL-6 expression while not affecting IL-8 expression and mitigates fibrotic processes, including vein graft disease [1].